Compare Eli Lilly And Co (LLY) vs Wolfspeed Inc (WOLF) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Wolfspeed (WOLF) trades at $30.62, down 2.39% today, with a bullish technical signal supported by moving averages. The company shows improving quarterly earnings performance with recent beats, though 2025 fundamentals reveal significant losses (-$1.61B net income) and negative margins. Recent news highlights expansion of 200mm silicon carbide substrates and AI infrastructure exposure. Analyst consensus price target sits at $54.32, representing 77% upside potential from current levels.

Wolfspeed presents a high-risk, high-reward opportunity with strong analyst upside potential but substantial fundamental challenges. The company's path to profitability depends on successful execution of its silicon carbide technology roadmap and achieving breakeven revenue targets. Near-term volatility is expected given ongoing operational challenges and investor investigations, while long-term prospects hinge on AI infrastructure adoption.